
Attend the world’s most comprehensive hematology/oncology event on Waldenstrom’s macroglobulinemia; the 11th International Workshop on Waldenstrom’s macroglobulinemia (IWWM-11).
The 11th International Workshop for Waldenstrom's Macroglobulinemia is being held October 27th through the 30th, 2022 in Madrid, Spain. The venue chosen for this meeting is one of Madrid’s premier hotels, Westin Palace Madrid, situated in the Las Letras quarter. The hotel nestles in one of the city’s most historic areas linking the city’s most enriching museums, Prado, Reina Sofia and Thyssen-Bornemisza, vibrant parks and gardens, and epicurean eateries. Onsite registration and check-in begin at 14:00 (2:00pm) on Wednesday, October 26th, conference sessions starting on Thursday, the 27th, at 8:00am.
The Workshop’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic system, by promoting targeted research, clinical care methods, education, training, and advocacy for Waldenstrom’s macroglobulinemia.
IWWM-11 will continue to support future research by including a Junior Investigator Poster presentation event with short oral presentations. Abstract submissions for poster presentations will begin in June 2022.
Read more: 11th International Workshop on Waldenstrom's Macroglobulinemia
The Waldenstrom's Macroglobulinemia Clinic at the DFCI is devoted to the care of patients with Waldenstrom's Macroglobulinemia and related IgM disorders, including IgM MGUS, Myeloma and Neuropathies.
For more information on the WM Clinic at DFCI, please visit the DFCI Center for Hematologic-Oncology/Waldenstrom's Macroglobulinemia Clinic.
Waldenström’s macroglobulinemia (WM) is a distinct B-cell malignancythat results from the accumulation, predominantly in the bone marrow, of clonally related B type lymphocytes, lymphoplasmacytic cells and plasma cells which secrete a monoclonal IgM protein.1 This condition is considered to correspond to the lymphoplasmacytic lymphoma (LPL) as defined by the World Health Organization classification system.2 Most cases of LPL are WM, with less than 5% of cases made up of IgA, IgG and non-secreting LPL ...